• Citer

Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.

par Hauser, Carl;Boffard, Kenneth;Dutton, Richard;Bernard, Gordon;Croce, Martin;Holcomb, John;Leppäniemi, Ari;Parr, Michael;Vincent, Jean Louis ;Tortella, Bartholemew;Dimsits, Jeannett;Bouillon, Bertil;CONTROL Study Group,
Référence The Journal of trauma, 69, 3, page (489-500)
Publication Publié, 2010-09

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes.